Charles River to Acquire Celsis

Charles River has announced plans to acquire Celsis International Ltd. Celsis is a leading provider of rapid microbial detection systems for quality control testing in the biopharmaceutical and consumer products industries. This acquisition complements our Endotoxin and Microbial Detection business, which is a leading provider of rapid endotoxin testing systems and bacterial identification services for biopharmaceutical manufacturing, creating the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products.

The addition of Celsis, with its Advance II, Accel and Innovate systems, will complement our recently introduced PTS-Micro, a rapid bacterial detection system for biopharmaceutical applications. The combination of Charles River and Celsis will drive significant value for our clients’ in-process and product release testing needs across a broad range of microbial detection applications.

The acquisition is expected to be completed in the third quarter of this year.